Allarity Therapeutics Statistics
Want to see ALLR full AI Analyst Report?
Allarity Therapeutics (ALLR) Stock Statistics & Valuation Metrics
Total Valuation
Allarity Therapeutics has a market cap or net worth of $14.88M. The enterprise value is $15.83M.
- Market Cap
- $14.88M
- Enterprise Value
- $15.83M
Share Statistics
Allarity Therapeutics has 15,910,724 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 15,910,724
- Owned by Insiders
- 7.69%
- Owned by Institutions
- 3.57%
Financial Efficiency
Allarity Therapeutics’s return on equity (ROE) is -1.14 and return on invested capital (ROIC) is -112.26%.
- Return on Equity (ROE)
- -1.14
- Return on Assets (ROA)
- -0.62
- Return on Invested Capital (ROIC)
- -112.26%
- Return on Capital Employed (ROCE)
- -1.28
- Revenue Per Employee
- 40.00K
- Profits Per Employee
- -1.40M
- Employee Count
- 8
- Asset Turnover
- 0.02
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Allarity Therapeutics is -1.15. Allarity Therapeutics’s PEG ratio is -0.01.
- PE Ratio
- -1.15
- PS Ratio
- 41.28
- PB Ratio
- 4.03
- Price to FCF
- -1.03
- Price to Operating Cash Flow
- -1.04
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Allarity Therapeutics had revenue of 320.00K and earned -11.23M in profits. Earnings per share was -0.78.
- Revenue
- 320.00K
- Gross Profit
- 320.00K
- Operating Income
- -12.61M
- Pretax Income
- -11.23M
- Net Income
- -11.23M
- EBITDA
- -11.05M
- Earnings Per Share (EPS)
- -0.78
Cash Flow
In the last 12 months, operating cash flow was -13.18M and capital expenditures -64,000, giving a free cash flow of -13.25M billion.
- Operating Cash Flow
- -13.18M
- Free Cash Flow
- -13.25M
- Free Cash Flow per Share
- -0.87
Dividends & Yields
Allarity Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -93.51%
- Earnings Yield
- -83.69%
Stock Price Statistics
- Beta
- 0.88
- 52-Week Price Change
- -28.11%
- 50-Day Moving Average
- 1.04
- 200-Day Moving Average
- 1.21
- Relative Strength Index (RSI)
- 45.04
- Average Volume (3m)
- 116.73K
Important Dates
Allarity Therapeutics upcoming earnings date is Apr 06, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 12, 2026
- Next Earnings Date
- Apr 06, 2027
- Ex-Dividend Date
- ―
Financial Position
Allarity Therapeutics as a current ratio of 2.13, with Debt / Equity ratio of 14.25%
- Current Ratio
- 2.13
- Quick Ratio
- 2.13
- Debt to Market Cap
- 0.09
- Net Debt to EBITDA
- 1.20
- Interest Coverage Ratio
- -68.14
Taxes
In the past 12 months, Allarity Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Allarity Therapeutics EV to EBITDA ratio is -1.81, with an EV/FCF ratio of -1.45.
- EV to Sales
- 58.09
- EV to EBITDA
- -1.81
- EV to Free Cash Flow
- -1.45
- EV to Operating Cash Flow
- -1.46
Balance Sheet
Allarity Therapeutics has $14.09M in cash and marketable securities with $0.00 in debt, giving a net cash position of $14.09M billion.
- Cash & Marketable Securities
- $14.09M
- Total Debt
- $0.00
- Net Cash
- $14.09M
- Net Cash Per Share
- $0.89
- Tangible Book Value Per Share
- ―
Margins
Gross margin is 107.54%, with operating margin of -3128.99%, and net profit margin of -3575.07%.
- Gross Margin
- 107.54%
- Operating Margin
- -3128.99%
- Pretax Margin
- -3575.07%
- Net Profit Margin
- -3575.07%
- EBITDA Margin
- -3203.19%
- EBIT Margin
- -3195.07%
Analyst Forecast
The average price target for Allarity Therapeutics is $11.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $11.00
- Price Target Upside
- 1104.82% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 91.38%
Scores
- Smart Score
- ―
- AI Score
- 44
